ClinicalTrials.gg
RecruitingNCT06189976Updated Dec 12, 2024

Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation

An interventional study of Rapid atrial pacing in Aortic Valve Disease, Transcatheter Aortic Valve Implantation and TAVI, sponsored by National and Kapodistrian University of Athens. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Aortic Valve Disease with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Aortic Valve Disease · Belgium.

Planned enrollment
7th of 10
400 · median 680
Started
2024
with 2 others
No phase
8 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
National and Kapodistrian University of Athens

Among the 15 studies in Aortic Valve Disease with a site in Belgium, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 with no phase, and was the 14th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

3 of the 15 studies in Aortic Valve Disease with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Aortic Valve Disease with a site in Belgium, or all of them as a file.
02

Study summary

Despite Transcatheter aortic valve implantation (TAVI) evolution regarding techniques, equipment and experience, the need for permanent pacemaker implantation (PPI) post-TAVI remains an important drawback. The electrophysiology testing to stratify the risk or necessity of PPI post-TAVI is endorsed by the up-to-date guidelines and consensus documents and it is a valuable cut-off based method. Part of the answer is maybe hidden in the easy and applicable testing of the atrioventricular conduction system through rapid atrial pacing (RAP) with a common temporary pacemaker lead. This trial is designed to investigate the role and value of RAP after TAVI as a predictor of the necessity of new PPI.

Read the detailed description
  1. INTRODUCTION AND RATIONALE Despite Transcatheter aortic valve implantation (TAVI) evolution regarding techniques, equipment and experience, the need for permanent pacemaker implantation (PPI) post-TAVI remains an important drawback. PPI rates range widely from 7.8% to 20.3% based on the CENTER collaboration results, whereas significant differences are observed among the available devices. Except for hospitalization prolongation and higher costs, the impact of PPI in long term follow-ups seems to not to be innocent as it is associated with increased all-cause mortality and rehospitalization rates according to a recent meta-analysis. Data from the SWEEDHEART registry demonstrated no difference in survival in a median follow-up of 2.7 years, however as TAVI is offered to younger patients the long-term impact of PPI needs to be thoroughly investigated.

    The electrophysiology testing to stratify the risk or necessity of PPI post-TAVI is endorsed by the up-to-date guidelines and consensus documents and it is a valuable cut-off based method. Despite individualization is essential, thresholds provide added security and aid on final decisions. Variable HV intervals have been evaluated in clinical trials; 70ms is supported by ESC guidelines, while 55 in the presence of left bundle branch block in an observational trial. HV interval measurement seems appealing, but there is lack of cut-off consensus, not every Cath lab is equipped with electrophysiologic test equipment and TAVI operators are not generally familiar with these procedures.

    Part of the answer is maybe hidden in the easy and applicable testing of the atrioventricular conduction system through rapid atrial pacing (RAP) with a common temporary pacemaker lead. Krishnaswamy et al. performed post-TAVI atrial pacing from 70 to 120 beats/min in 284 patients and concluded that those who did not develop pacing-induced Wenckebach atrioventricular block exhibited very low probability of PPI. On the contrary, a recent report from Tan et al., found that atrial pacing-induced Wenckebach pre or post-TAVI in a total of 253 patients did not predict PPI. In this trial balloon expandable valves were used that are associated with lower rates of PPI and it is possible that larger sample size is needed for safe conclusions.

  2. STUDY PROCEDURES TAVI will be planned to be performed with a temporary pacemaker lead in the right ventricle as a back-up for high grade conduction abnormalities or/and for on demand pacing. Before the procedure initiation, if the patient is stable and not pacemaker-dependant the temporary pacemaker electrode will be placed into the right atrium. This manoeuvre adds no cost and no additional risk for the patient as the electrode is already placed in the right chambers. Surface electrocardiogram will be recorded at the whole procedure. Atrial pacing will be initiated till Wenckebach AV block is observed and recorded or till the maximum atrial pacing rate is reached. The rate that AV block was observed will be catalogued. Maximum atrial pacing rate will be 150 beats/min (cycle length 400ms). After a successful TAVI procedure, if the patient is stable and not pacemaker-dependant the temporary pacemaker electrode will be placed again into the right atrium. The RAP test will be performed again.
  3. STUDY MONITORING 3.1 Responsibility of the investigators The investigators undertake to perform the study in accordance with this protocol and GCP. For the trial duration, the investigator(s) will maintain complete and accurate documentation including - but not limited to - medical records, trial progress records, laboratory reports, case report forms, signed informed consent forms, device accountability records, correspondence with the IRB, adverse event reports, and information regarding patient discontinuation or completion of the trial.

    3.2 Case report forms It is the responsibility of the investigator to maintain an accurate CRF to record all observations and other data pertinent to the clinical and laboratory investigations. All CRF should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of data. The data may be recorded either on hard copies or electronic data capture. This data will be monitored by and forwarded to the primary investigator (PI) in an expedited fashion.

  4. ADVERSE EVENTS All events will be registered in the CRF as defined by GCP. Adverse events will be actively checked during follow-up. Patient folder will provide contact information for patients in case of questions and when complications occur. Any complication will be managed at each centre per local practice.
03

Conditions studied

  • Aortic Valve Disease
  • Transcatheter Aortic Valve Implantation
  • TAVI

Keywords

  • TAVR
  • TAVI
  • Rapid atrial pacing
  • Aortic stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥18 years old.
  2. Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up.
  3. Patient has given written consent to participate in the trial.
  4. Patients undergoing TAVI as a treatment of severe aortic stenosis (AS).
  5. Patient in sinus rhythm.
  6. Patients planned for TAVI with utilization of temporary pacemaker electrode placement.

Exclusion criteria

Exclusion Criteria:

  1. Ongoing infection, including active endocarditis.
  2. Implanted permanent pacemaker and/or implantable cardioverter/defibrillator.
  3. Patients developing persistent second or third degree atrioventricular block (AV) after TAVI.
  4. Underlying rhythm other than sinus based on the surface leads monitoring after TAVI.
  5. Patients with second or third degree AV block identifyied on the screening pre-TAVI ECG.
  6. Enrolment in another study that competes or interferes with this study.
  7. Subject will not be able to comply with the follow-up requirements according to investigators' opinion.
  8. Pregnant or breast-feeding females or females who intend to become pregnant during the time of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Other
    Rapid atrial pacing

    Diagnostic test group (single group)

    Diagnostic Test: Rapid atrial pacing

Interventions

  • Diagnostic testRapid atrial pacing

    Rapid atrial pacing after TAVI

06

What researchers measure

Primary outcomes

  1. Permanent pacemaker implantation rates

    Rates of permanent pacemaker implantation after TAVI

    Time frame: 30 days

Secondary outcomes

  1. Mortality rates

    Rates of mortality after TAVI

    Time frame: 30 days

  2. Mortality rates

    Rates of mortality after TAVI

    Time frame: 6 months

  3. Permanent pacemaker implantation rates

    Rates of permanent pacemaker implantation after TAVI

    Time frame: 6 months

  4. Mortality rates

    Rates of mortality after TAVI

    Time frame: 12 months

  5. Permanent pacemaker implantation rates

    Rates of permanent pacemaker implantation after TAVI

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • CHU Saint-Pierre
    Brussels, 1000, Belgium
    Recruiting
    • Quentin de Hemptinne, MD, PhD · Contact
  • Hippocration Hospital
    Athens, Attiki 11527, Greece
    Recruiting
08

References and documents

Publications

  • Knecht S, Schaer B, Reichlin T, Spies F, Madaffari A, Vischer A, Fahrni G, Jeger R, Kaiser C, Osswald S, Sticherling C, Kuhne M. Electrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. J Am Heart Assoc. 2020 Mar 3;9(5):e014446. doi: 10.1161/JAHA.119.014446. Epub 2020 Feb 22. PubMed 32089049 ↗
  • Krishnaswamy A, Sammour Y, Mangieri A, Kadri A, Karrthik A, Banerjee K, Kaur M, Giannini F, Pagliaro B, Ancona M, Pagnesi M, Laricchia A, Weisz G, Lyden M, Bazarbashi N, Gad M, Ahuja K, Mick S, Svensson L, Puri R, Reed G, Rickard J, Colombo A, Kapadia S, Latib A. The Utility of Rapid Atrial Pacing Immediately Post-TAVR to Predict the Need for Pacemaker Implantation. JACC Cardiovasc Interv. 2020 May 11;13(9):1046-1054. doi: 10.1016/j.jcin.2020.01.215. Epub 2020 Apr 15. PubMed 32305392 ↗
  • Tan BE, Hashem A, Boppana LKT, Mohamed MS, Abbas SF, Faisaluddin M, Thakkar S, Ahmed AK, Hall C, Abtahian F, Rao M, Bhatt DL, Depta JP. Utility of rapid atrial pacing before and after TAVR with balloon-expandable valve in predicting permanent pacemaker implantation. Catheter Cardiovasc Interv. 2023 Nov;102(5):919-928. doi: 10.1002/ccd.30817. Epub 2023 Sep 12. PubMed 37698294 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Apr 2025, 13 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2023
First posted
Jan 5, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06189976
Collaborators
Centre Hospitalier Universitaire Saint Pierre
Responsible party
Leonidas Koliastasis (Interventional Cardiology Fellow, National and Kapodistrian University of Athens) — Principal investigator
First posted
Jan 5, 2024
Start date
Mar 1, 2024
Primary completion
Apr 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 12, 2024

Study contacts

Leonidas Koliastasis, MD, PhD
Contact
lkoliastasis@gmail.com
+30 6974270752
Leonidas Koliastasis
principal investigator · National and Kapodistrian University of Athens

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion